We observed differential expression of CSPG4 between BLCA tissues and normal tissues, establishing its significant associations with prognosis in patients with BLCA, the BLCA immune microenvironment, and PD1 immunotherapy outcomes for patients with BLCA. This evidence concerns the gene CSPG4 and bladder transitional cell carcinoma.